Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
GNI Group ( (JP:2160) ) just unveiled an update.
GNI Group Ltd. reported a significant decline in its financial performance for FY2024, with revenue and profits showing substantial year-on-year decreases. Despite the challenging financial results, the company remains optimistic about future growth, as reflected in its projections for FY2025, where it anticipates a revenue increase of 21.7%. The announcement highlights the inclusion of new entities in its consolidation scope, indicating strategic expansion efforts.
More about GNI Group
GNI Group Ltd. operates in the pharmaceutical industry, focusing on developing and commercializing innovative medicines. The company is listed on the Tokyo Stock Exchange, aiming to cater to global health needs through its research-driven approach.
YTD Price Performance: -3.77%
Average Trading Volume: 48
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €1.05B
Find detailed analytics on 2160 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue